Trial has finally arrived for the long-pending and much litigated Donovan class action against big tobacco in federal court in Massachusetts.  For big tobacco, delay apparently is perceived as a friend, but the delay also brought new findings supporting low dose CT scans (2010 post here, and 2015 post here), and a

Results are arriving from new science, and the news ties to medical monitoring claims against the tobacco industry.  Specifically, the National Cancer Institute issued yesterday a "breaking news" release regarding data emerging from long term, double-blind studies on using low dose CT scans to try to find lung cancers earlier in people with major smoking histories. The

Late stage cancers usually kill the victim, brutally. That’s especially true for the vicious cancer commonly known as mesothelioma. Therefore, researchers continue to seek out biomarkers to try to find tumors before they manifest themselves clinically. Success could provide great news for mesothelioma victims. Research success also would bring new issues for defendants and their insurers. 

The biomarker frontiers are expanding,

I’m setting aside James Hardie and Australia for a few days. News on Friday provides a great springboard for some comments in the same general area of what’s new in mass tort resolution thinking, and some points related to corporate actions to cope with/avoid/limit the corporate damage from mass tort claims.

How does big tobacco admit it  faces massive global tort

I’d love to take a few days to read and write about interesting thinking on mass torts and claims resolution issues. But that’s not possible right now. I do, however, have time to urge readers to spend some time on the November and December posts at the Mass Tort Litigation Blog.

At the blog, you

More great new science at the observable cellular level. As described below, scientists used tools to observe cellular level shapes, and then figured out a way to “staple” some proteins to better take on the needed shape to fit cellular receptors. How cool and important is this discovery? Very – the science is so good

Mayer Brown includes Herbert Zarov and other well regarded defense lawyers focused on toxic tort claims. Mr. Zarov and his colleagues recently published this DePaul Health Care Law Review article that sets out a defense perspective on the issues regarding medical monitoring claims in Illinois.

The outcome in Illinois will matter because Illinois holds an